AR120246A1 - Aminas heteroaril-bifenilas para el tratamiento de las enfermedades por pd-l1 - Google Patents

Aminas heteroaril-bifenilas para el tratamiento de las enfermedades por pd-l1

Info

Publication number
AR120246A1
AR120246A1 ARP200102872A ARP200102872A AR120246A1 AR 120246 A1 AR120246 A1 AR 120246A1 AR P200102872 A ARP200102872 A AR P200102872A AR P200102872 A ARP200102872 A AR P200102872A AR 120246 A1 AR120246 A1 AR 120246A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
independently selected
alkylene
haloalkyl
Prior art date
Application number
ARP200102872A
Other languages
English (en)
Spanish (es)
Inventor
Pingchen Fan
Christopher W Lange
Rebecca M Lui
Darren J Mmurtrie
Ryan J Scamp
Ju Yang
Yibin Zeng
Penglie Zhang
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of AR120246A1 publication Critical patent/AR120246A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP200102872A 2019-10-16 2020-10-16 Aminas heteroaril-bifenilas para el tratamiento de las enfermedades por pd-l1 AR120246A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962915771P 2019-10-16 2019-10-16

Publications (1)

Publication Number Publication Date
AR120246A1 true AR120246A1 (es) 2022-02-09

Family

ID=75538872

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200102872A AR120246A1 (es) 2019-10-16 2020-10-16 Aminas heteroaril-bifenilas para el tratamiento de las enfermedades por pd-l1

Country Status (20)

Country Link
US (3) US11866429B2 (enExample)
EP (1) EP4045037B1 (enExample)
JP (1) JP7686634B2 (enExample)
KR (1) KR20220083775A (enExample)
CN (1) CN114555080B (enExample)
AR (1) AR120246A1 (enExample)
AU (1) AU2020368392B2 (enExample)
BR (1) BR112022006279A2 (enExample)
CA (1) CA3152714A1 (enExample)
CL (2) CL2022000955A1 (enExample)
CO (1) CO2022004698A2 (enExample)
CR (1) CR20220216A (enExample)
EC (1) ECSP22038509A (enExample)
ES (1) ES3064674T3 (enExample)
IL (1) IL291735A (enExample)
MX (1) MX2022004450A (enExample)
PE (1) PE20221764A1 (enExample)
PH (1) PH12022550877A1 (enExample)
TW (1) TWI873207B (enExample)
WO (1) WO2021076688A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019165043A2 (en) 2018-02-22 2019-08-29 Chemocentryx, Inc. Indane-amines as pd-l1 antagonists
BR112021022659A2 (pt) 2019-05-15 2022-03-29 Chemocentryx Inc Compostos triarílicos para o tratamento de doenças pd-l1
KR102890201B1 (ko) 2019-07-10 2025-11-24 케모센트릭스, 인크. Pd-l1 억제제로서의 인단
ES3068390T3 (en) 2019-10-16 2026-05-29 Chemocentryx Inc Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
AU2020368392B2 (en) 2019-10-16 2026-01-08 Chemocentryx, Inc. Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases
EP4218936B1 (en) 2020-09-25 2026-04-01 House Wellness Foods Corporation Feed and composition containing lactic acid bacteria and fatty acid
CN115232109A (zh) * 2021-04-25 2022-10-25 广东东阳光药业有限公司 Pd-1/pd-l1类小分子抑制剂及其在药物中的应用
CN113135895A (zh) * 2021-04-30 2021-07-20 中国药科大学 一种新型联苯类衍生物及其制备方法与医药用途
CN115010658B (zh) * 2022-05-11 2023-06-27 南方医科大学 一种化合物及其制备方法与应用
WO2024134466A1 (en) * 2022-12-21 2024-06-27 Arbutus Biopharma Corporation Substituted arylamine compounds, substituted heteroarylamine compounds, and methods using same
WO2025171031A1 (en) * 2024-02-07 2025-08-14 Aligos Therapeutics, Inc. Pd-l1 compounds with a bicyclic group
WO2025171025A1 (en) * 2024-02-07 2025-08-14 Aligos Therapeutics, Inc. Pd-l1 compounds with a bicyclic group

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1268002A (en) 1917-09-12 1918-05-28 William M Goodwin Measuring instrument.
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
GB9604926D0 (en) 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
DK1531822T3 (da) 2002-06-12 2009-12-07 Chemocentryx Inc 1-aryl-4-substituerede piperazin derivater til anvendelse som CCR1 antagonister til behandlingen af inflammation og immunforstyrrelser
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
AU2003298661B2 (en) 2002-11-18 2007-05-10 Chemocentryx, Inc. Aryl sulfonamides
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
JP2007537275A (ja) 2004-05-12 2007-12-20 ケモセントリックス， インコーポレイテッド アリールスルホンアミド
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
AU2006204750C1 (en) 2005-01-14 2012-11-01 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
US20070010523A1 (en) 2005-06-22 2007-01-11 Chemocentryx, Inc. Azaindazole compounds and methods of use
US7790726B2 (en) 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
WO2007073432A2 (en) 2005-10-11 2007-06-28 Chemocentryx, Inc. Piperidine derivatives and methods of use
ATE486875T1 (de) 2005-11-10 2010-11-15 Chemocentryx Inc Substituierte chinolone und verwendungsverfahren
WO2007115232A2 (en) 2006-03-30 2007-10-11 Chemocentryx, Inc. Cxcr4 modulators
US7807704B2 (en) 2006-03-30 2010-10-05 Chemocentryx, Inc. Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2
PT2402319T (pt) 2006-03-31 2017-12-11 Novartis Ag Inibidores de dgat
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
PL2046762T3 (pl) 2006-07-14 2011-07-29 Chemocentryx Inc Triazolilofenylobenzenosulfonamidy
US20100234364A1 (en) 2006-07-14 2010-09-16 Arindrajit Basak Ccr2 inhibitors and methods of use thereof
CN101511800B (zh) 2006-07-14 2013-02-27 坎莫森特里克斯公司 三唑基苯基苯磺酰胺
EP2155712B1 (en) 2007-05-22 2016-09-07 ChemoCentryx, Inc. 3-(imidazolyl)-pyrazolo[3,4-b]pyridines
US7776877B2 (en) 2007-06-22 2010-08-17 Chemocentryx, Inc. N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
CA2692761C (en) 2007-07-12 2013-04-30 Chemocentryx, Inc. Fused heteroaryl pyridyl and phenyl benzenesulfonamides as ccr2 modulators for the treament of inflammation
CN102159213B (zh) 2008-09-11 2015-05-27 凯莫森特里克斯股份有限公司 4-氨基-3-(咪唑基)-吡唑并[3,4-b]嘧啶
CA2742306A1 (en) 2008-11-03 2010-05-06 Chemocentryx, Inc. Compounds for the treatment of osteoporosis and cancers
KR101701367B1 (ko) 2008-11-04 2017-02-02 케모센트릭스, 인크. Ｃｘｃｒ７의 모듈레이터
JP5819730B2 (ja) 2008-12-22 2015-11-24 ケモセントリックス，インコーポレイティド Ｃ５ａＲアンタゴニスト
US8293925B2 (en) 2009-09-21 2012-10-23 Chemocentryx, Inc. Pyrrolidinone carboxamide derivatives
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
DK2585064T3 (en) 2010-06-24 2017-07-24 Chemocentryx Inc C5aR antagonists
EA023521B1 (ru) 2011-11-14 2016-06-30 Сефалон, Инк. ПРОИЗВОДНЫЕ УРАЦИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ AXL И c-MET КИНАЗЫ
US8835419B2 (en) 2011-12-01 2014-09-16 Chemocentryx, Inc. Substituted anilines as CCR(4) antagonists
KR102031846B1 (ko) 2011-12-01 2019-10-14 케모센트릭스, 인크. Ｃｃｒ(4) 길항제로서의 치환된 벤즈이미다졸 및 벤조피라졸
EP2788000B1 (en) 2011-12-06 2018-05-30 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
DK2820006T3 (da) * 2012-02-29 2017-11-06 Chemocentryx Inc Pyrazol-1-yl benzen sulfonamider som ccr9 antagonister
AU2013352304C1 (en) 2012-11-29 2018-03-22 Chemocentryx, Inc. CXCR7 antagonists
EP2928474B1 (en) 2012-12-07 2018-11-14 ChemoCentryx, Inc. Diazole lactams
JP6306607B2 (ja) 2012-12-21 2018-04-04 ケモセントリックス，インコーポレイティド ジアゾールアミド
MX2016002544A (es) 2013-09-04 2016-06-17 Squibb Bristol Myers Co Compuestos utiles como inmunomoduladores.
TR201811077T4 (tr) 2013-09-06 2018-08-27 Aurigene Discovery Tech Ltd İmmünomodülatörler olarak 1,3,4-oksadiazol ve 1,3,4-tiyadiyazol türevleri.
RS57508B1 (sr) 2013-09-06 2018-10-31 Aurigene Discovery Tech Ltd 1,2,4-derivati oksadiazola kao imunomodulatori
CN105960237B (zh) 2013-12-02 2020-03-31 凯莫森特里克斯股份有限公司 Ccr6化合物
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
JP6767096B2 (ja) 2014-12-11 2020-10-14 リティックス バイオファーマ エイエス 免疫チェックポイント阻害剤の組み合わせ
RU2689988C2 (ru) 2015-04-21 2019-05-30 Джи Ти Икс, ИНК. Селективные лиганды-разрушители андрогенных рецепторов (sard) и способы их применения
EP3294728A1 (en) * 2015-05-13 2018-03-21 Selvita S.A. Substituted quinoxaline derivatives
RU2726206C2 (ru) 2015-05-21 2020-07-09 Кемосентрикс, Инк. Модуляторы ccr2
NL1041468B1 (en) 2015-09-08 2017-03-22 Bosch Gmbh Robert Metal ring component of a drive belt for a continuously variable transmisson.
EP3156405A1 (en) * 2015-10-13 2017-04-19 Boehringer Ingelheim International GmbH Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide
US10745382B2 (en) 2015-10-15 2020-08-18 Bristol-Myers Squibb Company Compounds useful as immunomodulators
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
MD3377488T2 (ro) 2015-11-19 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
ES2916874T3 (es) * 2015-12-17 2022-07-06 Incyte Corp Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
CA3009474A1 (en) 2015-12-22 2017-06-29 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3190103A1 (en) 2016-01-08 2017-07-12 Rijksuniversiteit Groningen Inhibitors of the pd-1/pd-l1 protein/protein interaction
BR112018014666B1 (pt) 2016-01-20 2024-01-02 Chemocentryx, Inc Compostos de 2-oxindol, seu uso e composição farmacêutica
SG11201808625QA (en) 2016-04-04 2018-10-30 Chemocentryx Inc SOLUBLE C5aR ANTAGONISTS
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
US10882833B2 (en) 2016-05-23 2021-01-05 Institute Of Materia Medica, Chinese Academy Of Medical Sciences Phenylate derivative, preparation method therefor, and pharmaceutical composition and uses thereof
EP3464279B1 (en) 2016-05-26 2021-11-24 Incyte Corporation Heterocyclic compounds as immunomodulators
SG11201811414TA (en) 2016-06-20 2019-01-30 Incyte Corp Heterocyclic compounds as immunomodulators
EP3474845B1 (en) 2016-06-27 2024-03-20 ChemoCentryx, Inc. Immunomodulator compounds
AU2017294231B2 (en) 2016-07-05 2021-09-09 Guangzhou Maxinovel Pharmaceuticals Co., Ltd Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
CN109689640B (zh) 2016-07-08 2022-01-04 百时美施贵宝公司 可用作免疫调节剂的化合物
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
US10144706B2 (en) 2016-09-01 2018-12-04 Bristol-Myers Squibb Company Compounds useful as immunomodulators
WO2018045142A1 (en) 2016-09-02 2018-03-08 Polaris Pharmaceuticals, Inc. Immune checkpoint inhibitors, compositions and methods thereof
KR102599339B1 (ko) 2016-12-20 2023-11-08 브리스톨-마이어스 스큅 컴퍼니 면역조정제로서 유용한 화합물
EP4223369A1 (en) 2016-12-22 2023-08-09 Incyte Corporation Immunomodulator compounds and methods of use
US10308644B2 (en) * 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
CN106674136B (zh) 2016-12-23 2019-07-02 中国医科大学 嘧啶类抗肿瘤化合物及其制备方法
US10654815B2 (en) 2016-12-29 2020-05-19 Shenzhen Chipscreen Biosciences Co., Ltd. Urea compound and preparation method and application thereof
CN108395443B (zh) 2017-02-04 2021-05-04 广州丹康医药生物有限公司 抑制程序性死亡受体配体1的环状化合物及其用途
JP7150745B2 (ja) 2017-03-27 2022-10-11 ブリストル－マイヤーズ スクイブ カンパニー 免疫調節剤としての置換イソキノリン誘導体
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
TW201841896A (zh) 2017-04-26 2018-12-01 大陸商南京聖和藥業股份有限公司 作為pd—l1抑制劑的雜環類化合物
CN108863963B (zh) 2017-05-08 2022-05-27 南京圣和药物研发有限公司 作为pd-l1抑制剂的杂环类化合物
KR102638253B1 (ko) 2017-05-31 2024-02-16 케모센트릭스, 인크. C5a 억제제로서의 6-5 융합 고리
JP7141129B2 (ja) 2017-05-31 2022-09-22 ケモセントリックス，インコーポレイティド Ｃ５ａ阻害剤としての５－５融合環
US10919852B2 (en) 2017-07-28 2021-02-16 Chemocentryx, Inc. Immunomodulator compounds
KR102670486B1 (ko) 2017-08-08 2024-05-28 케모센트릭스, 인크. 마크로사이클릭 면역조절제
CN109400522B (zh) 2017-08-18 2023-04-28 上海轶诺药业有限公司 一种具有pd-l1抑制活性的化合物、其制备方法及用途
EP3687525B1 (en) 2017-09-25 2025-10-29 ChemoCentryx, Inc. Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
US20190275015A1 (en) 2017-09-25 2019-09-12 Chemocentryx, Inc. Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
EP3692053A1 (en) 2017-10-03 2020-08-12 Bristol-Myers Squibb Company Immunomodulators
CN109665968B (zh) 2017-10-16 2022-02-22 四川科伦博泰生物医药股份有限公司 并环化合物及其制备方法和用途
CN109678796B (zh) 2017-10-19 2023-01-10 上海长森药业有限公司 Pd-1/pd-l1小分子抑制剂及其制备方法和用途
CN109721527B (zh) 2017-10-27 2024-03-12 广州丹康医药生物有限公司 一种新型抗pd-l1化合物、其应用及含其的组合物
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
WO2019120297A1 (zh) 2017-12-22 2019-06-27 上海海雁医药科技有限公司 免疫调节剂及其制法与医药上的用途
KR102666727B1 (ko) 2017-12-29 2024-05-21 광저우 맥시노벨 파마수티컬스 씨오., 엘티디. 방향족 비닐 또는 방향족 에틸계 유도체, 그의 제조방법, 중간체, 약물조성물 및 용도
US11414418B2 (en) 2018-01-23 2022-08-16 Bristol-Myers Squibb Company Compounds useful as immunomodulators
AU2019214089B2 (en) 2018-02-05 2021-02-11 Abbisko Therapeutics Co., Ltd. Biaryl derivative, preparation method therefor and pharmaceutical use thereof
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2019165043A2 (en) 2018-02-22 2019-08-29 Chemocentryx, Inc. Indane-amines as pd-l1 antagonists
US11578054B2 (en) 2018-03-01 2023-02-14 Bristol-Myers Squibb Company Compounds useful as immunomodulators
WO2019174533A1 (zh) 2018-03-13 2019-09-19 广东东阳光药业有限公司 Pd-1/pd-l1类小分子抑制剂及其在药物中的应用
CN112105610B (zh) 2018-03-13 2024-01-26 朱比连特普罗德尔有限责任公司 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物
SMT202300065T1 (it) * 2018-03-30 2023-05-12 Incyte Corp Composti eterociclici come immunomodulatori
US20210040118A1 (en) 2018-04-03 2021-02-11 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
CN112752756B (zh) 2018-05-11 2024-06-25 因赛特公司 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物
CN111886219B (zh) 2018-07-11 2023-04-25 上海和誉生物医药科技有限公司 免疫抑制剂及其制备方法和在药学上的应用
CN112384500B (zh) 2018-07-12 2024-05-14 贝达药业股份有限公司 免疫调节剂及其组合物和制备方法
PE20210642A1 (es) 2018-07-13 2021-03-23 Gilead Sciences Inc Inhibidores de pd-1/pd-l1
WO2020015717A1 (en) 2018-07-19 2020-01-23 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof
WO2020015716A1 (en) 2018-07-19 2020-01-23 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof
EP3831823A4 (en) * 2018-08-01 2022-04-27 Shanghai Ennovabio Pharmaceuticals Co., Ltd. PREPARATION AND USE OF AN AROMATIC COMPOUND WITH IMMUNEGULATORY FUNCTION
US20210236476A1 (en) 2018-08-29 2021-08-05 Chemocentryx, Inc. Methods of treating cancer with small molecule pd-l1 inhibitors
CN109336857A (zh) 2018-11-13 2019-02-15 南方医科大学 一种含取代联苯的黄酮及其应用
CN109438263A (zh) 2018-11-28 2019-03-08 南方医科大学 一种含取代联苯的萘及其应用
CN109503546A (zh) 2019-01-10 2019-03-22 南方医科大学 一种间苯二酚二苯甲醚及其应用
CN120463702A (zh) * 2019-01-31 2025-08-12 贝达药业股份有限公司 免疫调节剂，组合物及其方法
CN109776377B (zh) 2019-02-01 2021-08-24 沈阳药科大学 吲哚啉类化合物及其制备方法和应用
US20200297708A1 (en) 2019-03-19 2020-09-24 Chemocentryx, Inc. Combination Therapy Using a Chemokine Receptor 2 (CCR2) Antagonist and a PD-1 and/or PD-L1 Inhibitor
CN109776445B (zh) 2019-03-28 2022-12-06 中国药科大学 苯并噁二唑类化合物及其制备方法和医药用途
BR112021022659A2 (pt) 2019-05-15 2022-03-29 Chemocentryx Inc Compostos triarílicos para o tratamento de doenças pd-l1
CN110200959A (zh) 2019-05-30 2019-09-06 天津科技大学 一种黄酮类化合物的应用
CN110128415B (zh) 2019-05-31 2022-03-25 沈阳药科大学 用作免疫调节剂的吲哚啉类化合物及其制备方法
KR102841588B1 (ko) 2019-06-20 2025-08-01 케모센트릭스, 인크. Pd-l1 질환의 치료를 위한 화합물
KR102890201B1 (ko) 2019-07-10 2025-11-24 케모센트릭스, 인크. Pd-l1 억제제로서의 인단
BR112022007284A2 (pt) 2019-10-16 2022-07-05 Morphic Therapeutic Inc Inibição de integrina humana alpha-4 beta-7
ES3068390T3 (en) 2019-10-16 2026-05-29 Chemocentryx Inc Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
AU2020368392B2 (en) 2019-10-16 2026-01-08 Chemocentryx, Inc. Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases
TW202216694A (zh) 2020-06-23 2022-05-01 美商卡默森屈有限公司 使用雜芳基-聯苯醯胺衍生物治療癌症之方法

Also Published As

Publication number Publication date
JP7686634B2 (ja) 2025-06-02
IL291735A (en) 2022-05-01
US20240132495A1 (en) 2024-04-25
US20210130347A1 (en) 2021-05-06
KR20220083775A (ko) 2022-06-20
EP4045037A4 (en) 2023-11-15
WO2021076688A1 (en) 2021-04-22
BR112022006279A2 (pt) 2022-06-28
CN114555080B (zh) 2025-10-10
AU2020368392B2 (en) 2026-01-08
TW202128695A (zh) 2021-08-01
PH12022550877A1 (en) 2023-03-27
EP4045037A1 (en) 2022-08-24
ECSP22038509A (es) 2022-06-30
EP4045037C0 (en) 2026-01-28
JP2022551972A (ja) 2022-12-14
CL2022000955A1 (es) 2023-01-13
AU2020368392A1 (en) 2022-04-21
US11866429B2 (en) 2024-01-09
CO2022004698A2 (es) 2022-04-29
CL2025001073A1 (es) 2025-08-01
CR20220216A (es) 2023-01-09
US12371433B2 (en) 2025-07-29
TWI873207B (zh) 2025-02-21
US20250346598A1 (en) 2025-11-13
CA3152714A1 (en) 2021-04-22
ES3064674T3 (en) 2026-04-28
CN114555080A (zh) 2022-05-27
PE20221764A1 (es) 2022-11-11
MX2022004450A (es) 2022-05-03
EP4045037B1 (en) 2026-01-28

Similar Documents

Publication Publication Date Title
AR110139A1 (es) COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV
AR117616A1 (es) Compuestos anti-vih
AR108396A1 (es) Compuestos heterocíclicos como inmunomoduladores
AR110153A1 (es) ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV
AR117102A1 (es) Inhibidores de arg1 y/o arg2
AR120684A1 (es) INHIBIDORES DE HIF-2a
AR100438A1 (es) Pirazolopiridinas y pirazolopirimidinas
AR117424A1 (es) Inhibidores de los receptores erbb
AR094174A1 (es) Lactamas fusionadas de arilo y heteroarilo
AR106595A1 (es) COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
AR106865A1 (es) Piridinas sustituidas y métodos de uso
AR092108A1 (es) Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn
AR116798A1 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
AR088423A1 (es) Ligadores p1 ciclicos como inhibidores del factor xia
AR088748A1 (es) Macrociclos como inhibidores del factor xia
AR082152A1 (es) Derivados de n-(metilsulfonil)benzamida, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de nav1.7
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR087760A1 (es) Heterociclilaminas como inhibidores de pi3k
AR089865A1 (es) Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio
AR091981A1 (es) Dihidropiridona p1 como inhibidores del factor xia
AR088175A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR089285A1 (es) Derivados de betulina
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
AR108185A1 (es) Amidas terciarias y método para su uso